On the retinal toxicity of intraocular glucocorticoids
- PMID: 20654583
- DOI: 10.1016/j.bcp.2010.07.012
On the retinal toxicity of intraocular glucocorticoids
Abstract
Corticosteroids are hormones involved in many physiological responses such as stress, immune modulation, protein catabolism and water homeostasis. The subfamily of glucocorticoids is used systemically in the treatment of inflammatory diseases or allergic reactions. In the eye, glucocorticoides are used to treat macular edema, inflammation and neovascularization. The most commonly used glucocorticoid is triamcinolone acetonide (TA). The pharmaceutical formulation of TA is not adapted for intravitreal administration but has been selected by ophthalmologists because its very low intraocular solubility provides sustained effect. Visual benefits of intraocular TA do not clearly correlate with morpho-anatomical improvements, suggesting potential toxicity. We therefore studied, non-common, but deleterious effects of glucocorticoids on the retina. We found that the intravitreal administration of TA is beneficial in the treatment of neovascularization because it triggers cell death of endothelial cells of neovessels by a caspase-independent mechanism. However, this treatment is toxic for the retina because it induces a non-apoptotic, caspase-independent cell death related to paraptosis, mostly in the retinal pigmented epithelium cells and the Müller cells.
Copyright © 2010 Elsevier Inc. All rights reserved.
Similar articles
-
[Treatment of oedematous, proliferative and neovascular diseases by intravitreal triamcinolone acetonide].Klin Monbl Augenheilkd. 2003 Jun;220(6):384-90. doi: 10.1055/s-2003-40272. Klin Monbl Augenheilkd. 2003. PMID: 12830391 Review. German.
-
Glucocorticoids induce retinal toxicity through mechanisms mainly associated with paraptosis.Mol Vis. 2007 Sep 19;13:1746-57. Mol Vis. 2007. PMID: 17960113
-
Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.Acta Ophthalmol Scand. 2005 Dec;83(6):645-63. doi: 10.1111/j.1600-0420.2005.00592.x. Acta Ophthalmol Scand. 2005. PMID: 16396641 Review.
-
[Steroid therapy of oedematous and neovascular eye diseases].Klin Monbl Augenheilkd. 2003 Jun;220(6):383. doi: 10.1055/s-2003-40277. Klin Monbl Augenheilkd. 2003. PMID: 12830390 German. No abstract available.
-
Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema.Am J Ophthalmol. 2005 Oct;140(4):695-702. doi: 10.1016/j.ajo.2005.05.021. Am J Ophthalmol. 2005. PMID: 16226521 Clinical Trial.
Cited by
-
Dendrimer-Triamcinolone Acetonide Reduces Neuroinflammation, Pathological Angiogenesis, and Neuroretinal Dysfunction in Ischemic Retinopathy.Adv Ther (Weinh). 2021 Feb;4(2):2000181. doi: 10.1002/adtp.202000181. Epub 2020 Nov 9. Adv Ther (Weinh). 2021. PMID: 34527806 Free PMC article.
-
Temporal Association between Topical Ophthalmic Corticosteroid and the Risk of Central Serous Chorioretinopathy.Int J Environ Res Public Health. 2020 Dec 17;17(24):9455. doi: 10.3390/ijerph17249455. Int J Environ Res Public Health. 2020. PMID: 33348672 Free PMC article.
-
Peptidomimetics Therapeutics for Retinal Disease.Biomolecules. 2021 Feb 24;11(3):339. doi: 10.3390/biom11030339. Biomolecules. 2021. PMID: 33668179 Free PMC article. Review.
-
Mental stress as consequence and cause of vision loss: the dawn of psychosomatic ophthalmology for preventive and personalized medicine.EPMA J. 2018 May 9;9(2):133-160. doi: 10.1007/s13167-018-0136-8. eCollection 2018 Jun. EPMA J. 2018. PMID: 29896314 Free PMC article. Review.
-
Paraptosis-A Distinct Pathway to Cell Death.Int J Mol Sci. 2024 Oct 25;25(21):11478. doi: 10.3390/ijms252111478. Int J Mol Sci. 2024. PMID: 39519031 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical